Arvinas Inc   (ARVN)
Other Ticker:  
Price: $24.9900 $0.57 2.334%
Day's High: $25.85 Week Perf: 16.72 %
Day's Low: $ 24.52 30 Day Perf: 65.72 %
Volume (M): 612 52 Wk High: $ 42.52
Volume (M$): $ 15,299 52 Wk Avg: $26.44
Open: $24.84 52 Wk Low: $13.57

 Market Capitalization (Millions $) 1,352
 Shares Outstanding (Millions) 54
 Employees 133
 Revenues (TTM) (Millions $) 167
 Net Income (TTM) (Millions $) -485
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 3

Arvinas Inc
Arvinas Inc. is a biotechnology company that is based in New Haven, Connecticut. The company specializes in the development of a unique technology called PROTAC' or Proteolysis-Targeting Chimera. This involves designing and developing small-molecule drugs that can specifically degrade target proteins within cells. The technology has the potential to revolutionize the way we treat diseases, particularly in areas where there is a high unmet medical need.

Arvinas was founded in 2013 by Dr. Craig Crews, a prominent scientist in the field of protein degradation. The company has since grown to become a leading player in the biotech industry, with over 200 employees and an extensive research and development program.

The company's goal is to develop drugs for diseases that are currently difficult to treat or have no effective treatments available. This includes a focus on oncology, where Arvinas is developing drugs to target specific types of cancer. The company is also working on drugs for neurodegenerative diseases, cardiovascular disease, and certain viral infections.

One of the key advantages of Arvinas' PROTAC technology is its ability to target specific proteins within cells. This allows for a more precise and effective treatment approach, while minimizing side effects. The company is also working on developing drugs that can penetrate the blood-brain barrier, which will be critical in treating neurodegenerative diseases.

Arvinas has a pipeline of drugs in various stages of development. The company's lead drug candidate, ARV-110, is currently in a Phase 2 clinical trial for the treatment of prostate cancer. The company also has several other drugs in preclinical development, including drugs for breast cancer, ovarian cancer, and Alzheimer's disease.

In addition to its internal research and development efforts, Arvinas has established collaborations and partnerships with leading pharmaceutical companies. This includes a collaboration with Pfizer to develop drugs for oncology and a partnership with Genentech to develop PROTAC-based drugs for disease targets.

Overall, Arvinas Inc. is a cutting-edge biotech company with a mission to revolutionize the way we treat diseases. Its unique PROTAC technology has the potential to transform the biotech industry, and the company's extensive research and development efforts have positioned it as a leader in the field. With a strong pipeline of drugs in development and strategic partnerships with leading pharmaceutical companies, Arvinas is well-positioned for future success.

   Company Address: 5 Science Park New Haven 6511 CT
   Company Phone Number: 535-1456   Stock Exchange / Ticker: NASDAQ ARVN
   ARVN is expected to report next financial results on February 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enveric Biosciences Inc

The company announced operating shortfall in the third quarter of 2023

After the leaders in the Major Pharmaceutical Preparations sector, some overlooked businesses are impending with the respective earnings. ENVB said it has realized operating shortfall of $-3.448395 million, for the third quarter of 2023.

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Announces Revenue of $0.016 Million, Paving the Way for an Investor Opportunity

Cyclacel Pharmaceuticals Inc, a renowned biopharmaceutical company, recently released its financial results for the third quarter of 2023. While the revenue figures may seem low at $0.016 million, it is crucial to understand the context behind this decline. Despite the net deficit of $-5.982 million, larger than the previous year, strategic factors and upcoming events indicate that Cyclacel Pharmaceuticals Inc may present a significant opportunity for investors.
Revenue Insights and Future Expectations
Cyclacel Pharmaceuticals Inc's third-quarter revenue of $0.016 million reflects a temporary setback. However, it is essential to note that pharmaceutical companies often face fluctuations in revenue due to various factors such as drug development timelines, regulatory approvals, and clinical trials. These figures do not accurately reflect the long-term growth potential and overall strength of the company.

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc Faces Fiscal Disarray as Revenue Plummets

Financial News Report: Arrowhead Pharmaceuticals Inc Announces Q4 2023 Earnings
Arrowhead Pharmaceuticals Inc has reported its financial results for the fourth quarter of 2023 earnings season, revealing a significant increase in its loss per share. The company recorded a loss of $-1.02 per share, compared to $-0.81 per share in the same quarter the previous year, and a growth in loss from $-0.96 per share from the previous quarter.
Additionally, the company's revenue for the quarter declined by -49.02% to $16.10 million, down from $31.58 million in the same quarter a year before. However, sequentially, the revenue grew by 1.719% from $15.83 million.

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc. Faces Setback with Operating Loss in Q3 2023

Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.

Earth Science Tech Inc

The company released Revenue of $1.92772 million, in the fiscal interval closing September 30 2023

Earth Science Tech Inc, a leading company in the science and wellness industry, has recently released its financial results for the fiscal interval closing September 30, 2023. The results indicate a significant improvement in revenue, earnings, and profit margins. Additionally, the company's stock performance has been impressive, reflecting strong investor confidence. This article will outline the key facts from the financial results and provide an overview of the context surrounding Earth Science Tech Inc's recent achievements.
Financial Results:
1. Revenue: Earth Science Tech Inc achieved revenue of $1.92772 million in the fiscal interval closing September 30, 2023. This represents a substantial increase compared to the same quarter the previous year.


Arvinas Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com